August Troendle Sells 8,770 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 8,770 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $621.29, for a total value of $5,448,713.30. Following the completion of the transaction, the chief executive officer owned 515,153 shares of the company’s stock, valued at approximately $320,059,407.37. This represents a 1.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Medpace Stock Down 0.2%

Shares of Medpace stock traded down $1.15 on Thursday, hitting $615.29. The company’s stock had a trading volume of 221,328 shares, compared to its average volume of 333,335. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a fifty day moving average price of $582.78 and a 200-day moving average price of $508.65. The company has a market capitalization of $17.17 billion, a P/E ratio of 36.07, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the prior year, the company earned $3.10 EPS. The firm’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Hedge Funds Weigh In On Medpace

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Medpace in the second quarter valued at $1,323,047,000. Madison Asset Management LLC acquired a new stake in Medpace in the 2nd quarter worth about $128,956,000. Bank of America Corp DE acquired a new stake in Medpace in the 2nd quarter worth about $116,891,000. American Capital Management Inc. purchased a new stake in Medpace in the 2nd quarter valued at about $111,329,000. Finally, Franklin Resources Inc. grew its holdings in Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after buying an additional 183,645 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. BMO Capital Markets upped their target price on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Robert W. Baird increased their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Mizuho boosted their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research report on Monday. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $595.20.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.